Compare OMF & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OMF | PRAX |
|---|---|---|
| Founded | 1920 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 9.6B |
| IPO Year | 2013 | 2020 |
| Metric | OMF | PRAX |
|---|---|---|
| Price | $54.58 | $330.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 15 |
| Target Price | $69.17 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 1.6M | 364.5K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 7.65% | N/A |
| EPS Growth | ★ 54.72 | N/A |
| EPS | ★ 6.56 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $71.78 | N/A |
| Revenue Next Year | $6.89 | $6,395.88 |
| P/E Ratio | $8.37 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $38.00 | $26.70 |
| 52 Week High | $71.93 | $354.87 |
| Indicator | OMF | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 33.90 | 53.52 |
| Support Level | $51.93 | $290.36 |
| Resistance Level | $61.14 | N/A |
| Average True Range (ATR) | 1.88 | 18.34 |
| MACD | -0.02 | -2.56 |
| Stochastic Oscillator | 18.21 | 57.24 |
OneMain Holdings Inc is a consumer finance company providing loan products to customers through its branch network and the internet. The company provides personal loan products; offers credit cards; offers optional credit insurance and others; offers a customer-focused financial wellness program, and acquisitions and dispositions of assets and businesses. It provides origination, underwriting, and servicing of personal loans to non-prime customers. The company's reportable segment is Consumer and Insurance. The main source of revenue is net interest income.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.